Digital Health Doctor's Concern Health Care Healthcare Technology Latest Trends

Tepotinib for the treatment of Lung Cancer and other Medical Updates October -2020

Written by Mary Pooja

Tepotinib for the treatment of Lung Cancer

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). In this study, They evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced or metastatic NSCLC with a confirmed MET exon 14 skipping mutation. The primary end point was the objective response by independent review among patients who had undergone at least 9 months of follow-up. The response was also analyzed according to whether the presence of a MET exon14 skipping mutation was detected on liquid biopsy or tissue biopsy.

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2004407?query=featured_home

Comparison of serum levels of calcium, vitamin-D, phosphorous and C-reactive protein in acne patients versus healthy subjects

Acne vulgaris is among common bothersome skin problems. Recognition of contributing factors would help to prevent acne. Some dietary and inflammatory factors are among the suggested etiologies. According to the study results – Calcium, phosphorous, and CRP levels are not associated with acne incidence, but serum vitamin D is related to acne presentation.

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_home

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. In this double-blind, randomized trial, patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of the body surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically..

Link: https://www.nejm.org/doi/full/10.1056/nejmoa1811744

Facing COVID-19 in Ophthalmology Department

To provide useful guidelines, targeted at ophthalmology professionals, to minimize COVID-19 infection of both health-care workers and patients. In this review we present updated literature merged with our experience from hospitals in Bergamo, the epicenter of the COVID-19 European outbreak.

Link   https://www.tandfonline.com/doi/full/10.1080/02713683.2020.1752737

About the author

Mary Pooja